Brisbane, CA, United States of America

Scott McCauley


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Scott McCauley: Innovator in Immunotherapy

Introduction

Scott McCauley is a notable inventor based in Brisbane, California. He has made significant contributions to the field of immunotherapy, particularly in the development of methods for producing antigen-specific CD8+ T cells. His work has the potential to advance therapeutic approaches for diseases that can be treated with interleukin-10 agents.

Latest Patents

Scott McCauley holds a patent titled "Interleukin-10 production of antigen-specific CD8+ T cells and methods of use of same." This patent provides methods and compositions related to isolated CD8+ T cells that express a disease antigen-specific T cell receptor. The patent outlines how these CD8+ T cells can be obtained from the blood of subjects with diseases that are amenable to treatment using IL-10 agents. Additionally, it discusses therapeutic methods for administering these isolated T cells and the genetic modification of CD8+ T cells to express disease antigen-specific T cell receptors or chimeric antigen receptors.

Career Highlights

Scott McCauley is associated with Eli Lilly and Company, where he continues to work on innovative solutions in the field of immunotherapy. His research focuses on enhancing the efficacy of T cell therapies, which are crucial for treating various diseases.

Collaborations

Some of Scott's coworkers include John Brian Mumm and Ivan Ho Chan. Their collaborative efforts contribute to the advancement of research and development in immunotherapy.

Conclusion

Scott McCauley's work exemplifies the innovative spirit in the field of immunotherapy. His patent on antigen-specific CD8+ T cells represents a significant step forward in therapeutic methods for treating diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…